anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Rationale: Previous studies suggest that both irinotecan and Mytomycin C when administered alone have some efficacy against stomach cancer. Based on laboratory testing, researchers hypothesized that Mytomycin C may enhance the efficacy of irinotecan through an enzyme called Topoisomerase I. In addition, because Mytomycin C has severe side effects, combining these chemotherapy agents together may allow for lower dosages resulting in greater efficacy and reduced side effects. A recent study indicates that the combination of these drugs has promising anti-tumor activity against esophageal and stomach cancers. The current study builds on previous research to explore the most effective schedule for administering these drugs together.

Purpose: This study is evaluating the combination of irinotecan and Mytomycin C on two different treatment schedules in patients with advanced esophageal and stomach cancers. Characteristics of different genes will also be measured, along with genetic and molecular changes by comparing test results from the beginning and end of the study.

Treatment: Patients in this study will receive irinotecan and Mytomycin C in one of two treatment schedules. Both drugs will be administered in patients through an intravenous infusion. A computer will randomly assign patients to a treatment group. Group one will receive Mytomycin C on day 1 and irinotecan on days 2 and 9. Group two will receive Mytomycin C on days 1 and 8 and irinotecan on days 2 and 9. After day 9, patients in both groups will not be given any study drugs for almost three weeks to complete a four week cycle. Several tests and exams will be given throughout the study to closely monitor patients. Patients will continue receiving the study drugs until they experience disease growth or unacceptable side effects.
Dexmedetomidine is an alpha-2-adrenergic agonist. It is commonly used for sedation and as an adjunct to general anesthetics.
Orally administrable compsns. for protecting human skin against the effects of UV radiation comprise tyrosine and/or phenylalanine, a nontoxic Cu salt (I), carotene and vitamins E, PP and C. A unit dose pref. comprises 12-350mg tyrosine and/or phenylalanine, 1-5mg (I), 5-50 mg carotene, 5-50mg vitamin E, 9-90mg vitamin PP and 10-300 mg vitamin C. The carotene is beta-, gamma- or alpha-carotene or lycopene. (I) is Cu gluconate, citrate or carbonate. The vitamin PP is in the form of nicotinic acid or nicotinamide. The vitamin C is in the form of ascorbic acid, Ca or Na ascorbate or ascorbyl palmitate. The vitamin E is in the form of alpha-tocopherol or d- or dl-tocopherol acetate. The compsns. are formulated as tablet, capsules, pastilles, chewing gum, drinkable solns. or emulsions or food additives. ADVANTAGE - The compsns. have a synergistic effect, e.g. increasing the minimum erythematous dose of uv radiation by 34%.
On the Day2/3 of the menstrual cycle, qualified participants will be randomized into either of two groups. Participants in group B will receive IVM procedure.Other standard assisted reproductive treatments are similar and parallel between two groups.
Epilepsy is a highly prevalent neurological disorder characterized by recurrent seizures. Patients exhibit broad genetic, molecular, and clinical diversity involving mild to severe comorbidities. The factors that contribute to this phenotypic diversity remain unclear. Here we used publicly available datasets to systematically interrogate the expression pattern of 230 epilepsy-associated genes across human tissues, developmental stages, and central nervous system (CNS) cellular subtypes. We grouped genes based on their curated phenotypes into 3 broad classes: core epilepsy genes (CEG), where seizures are the dominant phenotype, developmental and epileptic encephalopathy genes (DEEG) that are associated with developmental and epileptic encephalopathy, and seizure-related genes (SRG), which are characterized by the presence of seizures and gross brain malformations. We find that compared to the other two groups of genes, DEEGs are highly expressed within the adult CNS, exhibit the highest and most dynamic expression in various brain regions across development, and are significantly enriched in GABAergic neurons. Our analysis provides an overview of the expression pattern of epilepsy-associated genes with spatiotemporal resolution and establishes a broad expression-phenotype correlation in epilepsy.
Background: Difficult laparoscopic cholecystectomy (LC) has been challenging for surgeons. Randhawa's system used operative time, complications, and conversion to define three difficulty grades. However, using fixed numbers of operative time as dividers among three groups might not be applicable universally. This study aimed to propose new classification with more flexible parameters. Methods: This retrospective cohort study was conducted with patients who underwent LC because of gallstone-related diseases between January 2017 and December 2021 at Thammasat University Hospital. The exclusion criteria were (1) emergent LC for acute cholecystitis, (2) other procedures performed in the same setting of LC, (3) incomplete information, and (4) LC converted to open cholecystectomy. Patients were categorized into three groups using Randhawa's classification. Thereafter, new classification using mean and standard deviation was applied to reclassify patients into three new groups. The comparison between two grading results was performed to prove the advantage of new classification. Results: Total of 523 patients who underwent LC were included with median age 59.3 years old and 60.8% female. By Randhawa classification, proportions of easy, difficult, and very difficult groups were 39%, 53.7%, and 7.3%, respectively. Then, the new operative-time dividers among three groups were changed from 60 and 120 minutes to mean and mean + 2SD, respectively. Reclassified three difficult groups were 38.9%, 57.1%, and 4%. The comparison demonstrated new classification as more flexible and more compatible with each individual surgeon. Conclusions: New surgeon-referenced grading system of difficult LC included surgeon's factors, not only unfavorable operative findings. This classification should be more flexible than the previous criterion-referenced one. Thai Clinical Trials Registry at https://www.thaiclinicaltrials.org with Number TCTR20220426003.
FIELD: chemistry.SUBSTANCE: invention relates to the field of macrolide chemistry, namely to previously unknown compounds – 5,4''-bis[(aryl)amino](thioxo) acetates of ivermectin of the general formula I (1 a-j) having antiparasitic activity, as well as to the method for their preparation and antiparasitic agents based on them. Method is that the ivermectin of formula III is reacted with acid chloride in an organic solvent medium in the presence of an amine type catalyst, followed by isolation of produced 5,4''-bis(chloroacetyl)ivermectin and treatment with its pre-prepared solution of sulfur and amine in DMF. As the organic solvent, for example, methylene chloride or chloroform is used. As the amine type catalyst, for example, pyridine, 2,6-lutidine or triethylamine is used. To improve the solubility of sulfur and to create a homogeneous reaction medium, triethylamine is added to the previously prepared sulfur and amine solution in DMF. Invention also relates to antiparasitic agents based on compounds of general formula I. 1a-jR=,,,,,,,III.EFFECT: technical result of the proposed invention consists in the preparation of new compounds of general formula I possessing high antiparasitic activity, allowing them to be used to create effective antiparasitic agents compatible with auxiliary substances ointments, which widens the range of anti-parasitic products that can be used for external use in the fight against parasites.8 cl, 1 tbl, 11 ex
The Standard IMT group will receive a Threshold® Inspiratory Muscle Trainer. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject. Subjects will be instructed to perform up to 36 breaths daily. To compare with TIRE training, we will ask participants to perform this within a 30-minute session.
A computer-implemented method of performing, by a system of augmented intelligence, urinary analysis implemented on one or more processors and associated memory is provided. The method includes a first step of receiving an image of urine microscopy sample. The method includes a second step of detecting microscope light and a magnification technique. The method includes a third step of classifying said image according to the presence of urinary sediments by a machine learning model. The method includes a fourth step of identifying sediments in said image by said trained machine learning model if urinary sediments are present. The method includes a fifth step of classifying said urinary sediments by said trained machine learning model. The method includes a sixth step of generating a report of a presence or an absence of clinically significant urinary sediments in said urine microscopy sample.
Each patient were required to inhale via Ellipta® in a randomized cross-over sequence. The randomization numbers were generated using 6 sequences: BEH, EHB, HBE, BHE, EBH, HEB (B: Breezhaler, E: Ellipta, H: Handihaler).
In this project, Kinesio Taping will be applied to the Kinesio Taping group to reduce pain and support circulation. In this study, space correction method to reduce pain and lymphatic correction technique to support circulation will be applied from Kinesio Taping methods. In the study, in order to determine the susceptibility to allergy to kinesio tape, a five cm application will be made on the outer lateral region of the arms of pregnant women and waited for 10 minutes. Before the application, the physiotherapist will clean the application area with volatile alcohol for correct and good adhesion of the tape. Four bands of 10 cm each will be cut for the application. In order to protect the tape during the movement of the person, all corners will be oval shaped and the kinesio tape will be adhered to the BL-40 and BL-57 points bilaterally using 25-50% tension with the space correction method.
FIELD: medicine, pharmacy. SUBSTANCE: invention elates to hemostatic agent containing calcium alginate as a base, vegetable extracts, ε- aminocaproic acid. Agent is used for ceasing capillary and mixed bleedings in traumatic injures of skin integument and muscle tissues in surgery practice. Agent shows effective hemostatic property and absence of allergic responses. EFFECT: valuable medicinal properties of agent. 1 tbl
Patients will receive Omacetaxine at Dose level 2.0mg/m\^2, Cytarabine and Idarubicin as part of the treatment plan. Study participants will follow in outpatient clinic at least every 2 months for a total of 6 months. A final study visit will occur 6 months (+/-1 week) after the last dose of Omacetaxine. This visit will end study participation unless there is ongoing toxicity that is at least possibly related to study treatment. In this case, the patient will be followed as medically appropriate until resolution or stabilization of the adverse event.
OBJECTIVE: COVID-19 induces the development of autoimmune diseases, including SLE, which are characterised by inflammation, autoantibodies and thrombosis. However, the effects of COVID-19 on SLE remain unclear.
METHODS: We investigated the effects of COVID-19 on SLE development and progression in three animal models. Plasmids encoding SARS-CoV-2 spike protein and ACE2 receptor were injected into R848-induced BALB/C lupus mice, R848-induced IL-1 receptor antagonist knockout (KO) lupus mice and MRL/lpr mice. Serum levels of albumin and autoantibodies, lymphocyte phenotypes and tissue histology were evaluated.
RESULTS: In R848-induced BALB/C lupus mice, the SARS-CoV-2 spike protein increased autoantibody and albumin levels compared with vehicle and mock treatments. These mice also exhibited splenomegaly, which was further exacerbated by the spike protein. Flow cytometric analysis revealed elevated T helper 1 cell counts, and histological analysis indicated increased levels of the fibrosis marker protein α-smooth muscle actin. In KO mice, the spike protein induced splenomegaly, severe kidney damage and pronounced lung fibrosis. In the MRL/lpr group, spike protein increased the serum levels of autoantibodies, albumin and the thrombosis marker chemokine (C-X-C motif) ligand 4.
CONCLUSION: COVID-19 accelerated the development and progression of lupus by inducing autoantibody production, fibrosis and thrombosis.
The winter subtype of seasonal affective disorder (SAD) is characterized by episodes of major depression in the fall and winter, with remission of these episodes in the spring and summer. SAD disrupts the lives of millions of Americans, who experience symptoms such as restless agitation, increased appetite and weight gain, and reduced energy and motivation. Bright light treatment, while shown to be effective in improving SAD in 75% of cases, only causes a full remission in 50% of cases. If doctors had a diagnostic tool to determine which patients would respond to bright light therapy, they could make better decisions about whether to prescribe bright light as treatment. This study will examine a possible diagnostic tool-a single, 1-hour bright light session-for predicting improvement in SAD symptoms over an extended course of bright light treatment. Additionally, because many symptoms of SAD (like weight gain and sedentary lifestyle) correspond to cardiovascular risk, this study will examine whether bright light treatment correlates with improved cardiovascular health.

Participants with SAD will be randomly assigned to first receive a 1-hour session of either bright light or the placebo, red light. Then all participants will switch and receive a 1-hour session of the other type of light. Red light has been accepted as a placebo in previous SAD studies because it does not suppress melatonin or shift circadian rhythms. Before and after each light session, participants will have their SAD symptoms evaluated in a clinical interview and self-report measure. After these two light sessions, all participants will receive instructions for administering bright light treatment on their own at home. For the next 6 weeks, participants will administer the bright light to themselves for 1 hour every morning. Every week they will undergo clinical interviews by phone and will mail in self-report measures, some completed daily and some weekly, to the researchers. The participants will have checkups and interviews in person on Weeks 4 and 6. At the two time periods, SAD symptoms and indicators of cardiovascular risk, such as appetite and sleep loss, will be evaluated. The participant responses to bright light and red light at the initial session will be compared with the participant responses to the subsequent 6-week treatment.
The compound contains nutritive products and various additives and is produced using an external energy source. The nutritive products are cooking salt, sugar and honey in various proportions. Sea salt is sometimes used instead of cooking salt. The quantities in gramme per litre are as follows: cooking or sea salt 1-400, sugar 1-3000, honey 1-6000. The additives used are chlorides or carbonates of alkaline or alkaline-earth metal, or sea salt, or a mixture of these compounds in a quantity of 1-320/gramme/litre. Alternatively, these additives can be trace elements in the form of chlorides or carbonates of copper, molybdenum, manganese, iron, cobalt or nickel in a quantity of 1-4/gramme/litre. The process involves subjecting the compound to electrical pulses lasting between 1 x 10⁻⁸ and 1 sec., with a potential wave slope at the trailing edge of 1 x 10⁻⁸ - 1 x 10¹³ V/sec., a duty cycle of 1 - 10⁴ and an electrical field potential between the electrodes of 10 - 9 x 10⁴ V/cm. The electrical pulses sometimes undergo initial conversion to magnetic, electromagnetic, light or audio pulses.
As a result of this study, the possible changes in balance and functional jump performances of athletes who have previously had unilateral lower extremity injuries will be examined with the dual-task paradigm. In line with these results, it will be possible to comment on the balance and functional hop test performances of the athletes together with the cognitive task. Balance measurements and functional performance evaluations are used in the decision to return to sports after previous injuries. After the measurements, the affected and unaffected side are compared and an evaluation is made. However, even with these tests and evaluations, athletes are injured again when they return to sports. One of the reasons for this may be that the protective and controlled environment applied during rehabilitation is less challenging and requires less attention when compared to the competitive and sports environment in which the person is involved. For this reason, the investigator think that the evaluations and tests used in the decision to return to sports include both cognitive and physical performance by forcing the attention demands of the person, and it may be more effective in determining the real performance of the person. Thus, the use of physical assessments applied with simultaneous cognitive tasks can be used in the evaluation of the athletes during the return to sports by calculating the possible measurement differences between the affected and unaffected sides compared to the classical procedure, and in the planning of preventive rehabilitation programs of the athletes if there is a decrease in performance in the measurements applied as a dual task. It also contributes to studies that examine performance together with the dual task previously applied to athletes. Secondly, by examining the relationship between balance and functional hop test parameters, it will be determined how effective the independent variables are on each other. If the performance of individuals who have had a previous injury change with the dual task and the mechanisms of these possible changes are known, protective and performance-enhancing strategies can be developed, the cognitive and physical preparation of the athletes for the sports environment can be accelerated, and the risks of re-injury of the athletes can be reduced, as a result of which medical costs can be reduced.
The use of clinical pharmacists in primary care has improved the control of several chronic cardiovascular conditions. However, many private physician practices lack the resources to implement team-based care with pharmacists. The purpose of this study was to evaluate whether a centralized, remote, clinical pharmacy service could improve guideline adherence and secondary measures of cardiovascular risk in primary care offices in rural and small communities.

This study was a prospective trial in 12 family medicine offices cluster randomized to either the intervention or usual care. The intervention was delivered for 12 months, and subjects had research visits at baseline and 12 months. The primary outcome was adherence to guidelines, and secondary outcomes included changes in key cardiovascular risk factors and preventative health measures. We enrolled 302 subjects.
BACKGROUND: It has been hypothesised that frailty is the root cause of clinically observed but rarely systematically measured unstable disability among older adults. In this study, we measure the extent of short-term disability fluctuations and estimate their association with frailty using intensive longitudinal data.
METHODS: Repeated measurements of disability were collected under a measurement burst design in the FRequent health Assessment In Later life (FRAIL70+) study. A total of 426 community-dwelling older adults (70+) in Austria were interviewed about difficulties with basic, instrumental and mobility-related activities of daily living biweekly up to a total of 14 times in two measurement bursts (2891 and 2192 observations). Baseline frailty was assessed with both physical frailty (FP) and the frailty index (FI). Disability fluctuations were measured with the intra-individual interquartile range (iIQR) and estimated with a two-step generalised mixed regression procedure.
RESULTS: Fewer participants were frail at baseline according to FP (11%) than FI (32%). Frail study participants reported not only more severe disability but also had more short-term disability fluctuations (iIQR = 1.0-1.5) compared with their robust counterparts (iIQR = 0). Regression models indicated that baseline frailty was associated with 2-3 times larger short-term disability fluctuations, which were also more prevalent among women, and increased with age and disability severity.
CONCLUSION: Compared with those who were robust, frail older adults were characterised by not only more severe but also more unstable disability. Short-term disability fluctuations are closely tied to disability severity. Future studies should assess both stressors that may cause disability fluctuations among frail older adults as well as their potential consequences to inform frailty-centred care.
PURPOSE: To obtain an antimycotic medicine containing nikkomycin, useful for treating the infection of bacteria or fungi, and capable of being orally or parenterally used. CONSTITUTION: This antimycotic medicine contains a nikkomycin selected from nikkomycin Z, Zt, ZH, X, Xt, B, Bx, C and Cx. The combination of the nikkomycin with an azole antimycotic medicine exhibits synergism on the antimycotic effect. The nikkomycin and the azole antimycotic medicine are compounded in a ratio of 1:1 to 30:1, preferably 3:1 to 10:1. The antimycotic medicine can be prepared in the form of tablets, capsules, pills, granules, suppositories, solutions, coatings, ointments, gels, creams, lotions, powders, spray, etc. The antimycotic medicine is administered at a daily dose of 1-1000mg/kg, preferably 10-100mg/kg.
A sachet formed from a water soluble plastics material comprises a personal care composition, which includes at least one surfactant together with an effervescent base material, wherein the base material liberates a gas when in contact with a sufficient amount of water. Typically, the base material comprises a carbonate and/or a bicarbonate, e.g. sodium bicarbonate in combination with an acid, such as citric acid. The base material and the surfactant(s) may be provided in powdered or granular form. The surfactant(s) may be anionic, nonionic, cationic, amphoteric or mixtures thereof The plastics material may be polyvinyl alcohol, polyvinyl pyrrolidine, a starch-based polymer, cellulose, or an alginate. The sachet is preferably for addition to bath water.
Control group participants receive an educational brochure from American Heart Association entitled "Understanding and Controlling Your High Blood Pressure Brochure" (product code 50-1639). Every participant is provided with a validated home blood pressure monitor (Omron, Model PB786N), that as an evidence-based approach to lower blood pressure, would be considered "enhanced usual care" at this time. All participants who have uncontrolled hypertension (blood pressure \>140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for uncontrolled hypertension. For participants with uncontrolled hypertension who do not have a physician, we work participants to provide access within constraints of their health insurance.